vHIT Testing for Presentation of Dizziness at a Comprehensive Stroke Center
Is Video Head Impulse Testing a Safe, Reliable and Cost Effective Method of Assessment of Patients Presenting for Dizziness at a Comprehensive Stroke Center?
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Christine Holmstedt, DO
- Phone Number: 8437923020
- Email: Holmsted@musc.edu
Study Contact Backup
- Name: Sinead Farrelly, DPT
- Email: farrelsi@musc.edu
Study Locations
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adults between the ages of 18-90
- Admitted to the MUSC ED with symptomatic dizziness, concerning for a stroke vs peripheral vestibular dysfunction.
Exclusion Criteria:
- Prisoners
- COVID +
- Cognitively Impaired Individuals
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: vHIT testing
For the research portion of this study, following standard of care examinations listed above, the patient would have a vHIT headset placed on their head for approximately 3-5 minutes to test if they exhibit corrective saccadic movements and to measure gain reduction to identify vestibular hypofunction.
During vHIT testing a commercially available mono-ocular video oculography system will be donned on the patient.
Subjects will be instructed to maintain fixation at a target from 1 m distance.
A study team member will deliver at least 5 head impulses per side in the horizontal and vertical planes with unpredictable timing and direction.
A neurotologist will then evaluate the VOR gain or the ratio of eye velocity over-head velocity.
The presence of refixation (catch-up) saccades, either overt or covert, will be evaluated by the study team.
In line with previous literature, the vHIT testing will be considered to be abnormal if VOR gain is <0.8 in the presence of refixation saccades .
|
During vHIT testing a commercially available mono-ocular video oculography system will be donned on the patient.
(Interacoustics EyeSeeCam vHIT 3rd Generation Tests: VOR of lateral, RALP, & LARP canals.
SW: 3rd generation VE525 software.
HW: laptop PC, lightweight monocular video goggles).
Subjects will be instructed to maintain fixation at a target from 1 m distance.
A study team member will deliver at least 5 head impulses per side (10-20° angle, duration 150-200 ms, peak velocity of >150°/s) in the horizontal and vertical planes with unpredictable timing and direction.
A neurotologist will then evaluate the VOR gain or the ratio of eye velocity over-head velocity.
The presence of refixation (catch-up) saccades, either overt or covert, will be evaluated by the study team.
In line with previous literature, the vHIT testing will be considered to be abnormal if VOR gain is <0.8 in the presence of refixation saccades .
A standard neurologic evaluation will be performed including a National Institute of Health Stroke Scale and imaging if symptoms and NIHSS warrant.
|
|
Active Comparator: Standard of Care
The intervention group will be compared to standard of care provided to patients currently admitted for dizziness.
Standard of care includes National Institute of Health Stroke Scale evaluation, evaluation by a neurologist, and a CT scan or MRI if warranted.
|
A standard neurologic evaluation will be performed including a National Institute of Health Stroke Scale and imaging if symptoms and NIHSS warrant.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sensitivity & Specificity of vHIT device
Time Frame: This will be performed once all results are compiled, not to exceed 90 days after study completion.
|
Sensitivity and specificity of the vhit to detect peripheral vestibular dysfunction in an acute presentation of vertigo
|
This will be performed once all results are compiled, not to exceed 90 days after study completion.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to perform testing
Time Frame: From time the study team member arrives to patient's location until vHIT testing is complete, not to exceed 1 hour.
|
The time it takes to perform vHIT testing on a participant admitted for dizziness in the hospital environment.
|
From time the study team member arrives to patient's location until vHIT testing is complete, not to exceed 1 hour.
|
|
Predictive Value
Time Frame: At the time results are compared from vHIT testing to CT scan, not to exceed 30 days post testing.
|
We will measure positive predicitive value of vHIT to determine peripheral vestibular involvement in a participant who presents with dizziness.
|
At the time results are compared from vHIT testing to CT scan, not to exceed 30 days post testing.
|
|
Cost Analysis
Time Frame: This will be performed once all results are compiled, not to exceed 90 days after study completion.
|
We will examine the cost reduction that would have occured if vhit was incorporated in decision making for stroke workup and/or hospital admission
|
This will be performed once all results are compiled, not to exceed 90 days after study completion.
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Pro00129771
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.